tirzepatide protocol Dosing Chart 2026: 2.5-15 mg Titration & Units GLP-1 Protocol Management in Your

If you inject in the evening, you may experience peak appetite suppression overnight and into the next morning, which could reduce breakfast cravings but might make dinner uncomfortable

Glutamate flavoring

Mechanism of Action Tirzepatide: Dual incretin (GIP + GLP-1) enhanced metabolic impact Wegovy: GLP-1 receptor agonist now with higher receptor engagement Weight Loss Outcomes Tirzepatide: ~22% weight reduction in trials Wegovy 7.2 mg: ~2021% weight reduction The efficacy gap is narrowing significantly Cardiometabolic Profile Wegovy: Strong, established cardiovascular outcome data Tirzepatide: Superior glycemic control and insulin sensitivity Safety & Tolerability Both therapies show dose-dependent GI side effects Overall safety profiles remain comparable The Big Picture We are witnessing a shift from: Single-hormone optimization (high-dose semaglutide) to Multi-hormone targeting (tirzepatide) Conclusion While Wegovy is rapidly closing the efficacy gap with dose escalation, Tirzepatide continues to lead as a next-generation metabolic therapy

Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, et al

Insel, T